New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Bibliographic Details
Main Author: Almeida, Ana G.
Publication Date: 2019
Other Authors: Almeida, António, Melo, Teresa, Guerra, Lurdes, Lopes, Luís, Ribeiro, Patrícia, Duarte, Marta, Mota, Alexandra, Carvalho, Ricardo Fontes
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10451/37247
Summary: © 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
id RCAP_2af60bfd1f18aee0470a7a185266239d
oai_identifier_str oai:repositorio.ulisboa.pt:10451/37247
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemiaNovas perspetivas para a abordagem dos efeitos cardiovasculares dos inibidores da tirosinacinase em doentes com leucemia mieloide crónicaCardio-oncologyChemotherapyTyrosine kinase inhibitorsCardiotoxicityChronic myeloid leukemia© 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The use of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia has significantly altered the prognosis of this disease, enabling close to normal life expectancy. Despite their undeniable benefits, the use of TKIs is associated with an increased risk of side effects on the cardiovascular system, particularly of atherothrombotic events. It is therefore necessary to understand and prevent the adverse effects of these drugs, in order to enable antileukemic therapy to continue and to minimize patients’ toxic exposure. This multidisciplinary consensus document, developed through a collaboration between hematologists and cardiologists, aims to review the cardiovascular toxicity associated with various TKIs and to establish recommendations for the follow-up of these patients. Measures are also proposed for the assessment and reduction of cardiovascular risk in these patients and referral criteria, and relevant drug interactions are discussed.O uso dos inibidores da tirosina cínase (ITC) para o tratamento da leucemia mieloide crónica alterou significativamente o prognóstico dessa doença e permitiu uma esperança de vida praticamente normal. Apesar dos seus inegáveis benefícios, o uso dos ITC está associado a um aumento do risco de efeitos colaterais sobre o sistema cardiovascular, nomeadamente no risco de eventos aterotrombóticos. Torna-se por isso necessário conhecer e prevenir os efeitos adversos desses fármacos de modo a permitir a continuação da terapêutica antileucémica e minimizar a toxidade para os doentes. Este documento multidisciplinar, elaborado através de uma colaboração entre hematologistas e cardiologistas de vários serviços hospitalares portugueses, tem por objetivo rever a toxidade cardiovascular associada aos vários ITCs e estabelecer sugestões para o seguimento desses doentes. São ainda propostas medidas para a avaliação e redução do risco cardiovascular desses doentes, critérios de referenciação e discutidas interações medicamentosas relevantes.ElsevierRepositório da Universidade de LisboaAlmeida, Ana G.Almeida, AntónioMelo, TeresaGuerra, LurdesLopes, LuísRibeiro, PatríciaDuarte, MartaMota, AlexandraCarvalho, Ricardo Fontes2019-02-28T16:33:37Z2019-012019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/37247engRev Port Cardiol. 2019;38:1-92174-204910.1016/j.repc.2017.10.013info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-17T14:04:22Zoai:repositorio.ulisboa.pt:10451/37247Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T03:02:06.442817Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Novas perspetivas para a abordagem dos efeitos cardiovasculares dos inibidores da tirosinacinase em doentes com leucemia mieloide crónica
title New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
spellingShingle New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Almeida, Ana G.
Cardio-oncology
Chemotherapy
Tyrosine kinase inhibitors
Cardiotoxicity
Chronic myeloid leukemia
title_short New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
title_full New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
title_fullStr New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
title_full_unstemmed New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
title_sort New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
author Almeida, Ana G.
author_facet Almeida, Ana G.
Almeida, António
Melo, Teresa
Guerra, Lurdes
Lopes, Luís
Ribeiro, Patrícia
Duarte, Marta
Mota, Alexandra
Carvalho, Ricardo Fontes
author_role author
author2 Almeida, António
Melo, Teresa
Guerra, Lurdes
Lopes, Luís
Ribeiro, Patrícia
Duarte, Marta
Mota, Alexandra
Carvalho, Ricardo Fontes
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Almeida, Ana G.
Almeida, António
Melo, Teresa
Guerra, Lurdes
Lopes, Luís
Ribeiro, Patrícia
Duarte, Marta
Mota, Alexandra
Carvalho, Ricardo Fontes
dc.subject.por.fl_str_mv Cardio-oncology
Chemotherapy
Tyrosine kinase inhibitors
Cardiotoxicity
Chronic myeloid leukemia
topic Cardio-oncology
Chemotherapy
Tyrosine kinase inhibitors
Cardiotoxicity
Chronic myeloid leukemia
description © 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
publishDate 2019
dc.date.none.fl_str_mv 2019-02-28T16:33:37Z
2019-01
2019-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/37247
url http://hdl.handle.net/10451/37247
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Rev Port Cardiol. 2019;38:1-9
2174-2049
10.1016/j.repc.2017.10.013
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833601569781710848

Similar Items